α-particle emitting radionuclides, such as 225Ac or 213Bi, have been used to radiolabel PSMA-617, in order to increase the anti-tumor activity, and to treat relapsed patients with no major risk of side effects. This evidence concerns the gene FOLH1 and neoplasm.